A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease
Latest Information Update: 12 May 2022
Price :
$35 *
At a glance
- Drugs AXO Lenti PD (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Sio Gene Therapies [CEASED]
- 27 Apr 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Mar 2021 Planned End Date changed from 1 May 2022 to 1 Aug 2022.
- 15 Mar 2021 Planned primary completion date changed from 1 May 2021 to 1 Aug 2021.